Characteristics of Study Patients (Cases and Controls).

*<p>Net family income in Canadian dollars (1 Canadian dollar = 1.2 US dollars).</p>†<p>Romano commorbidity score calculated using data from 365 days prior to the index date.</p>‡<p>History within 5 years prior to the index date.</p>§<p>Dispensing of a drug within 365 days prior to index date.</p

Risk of Myocardial Infarction for Rosiglitazone Compared to Pioglitazone and Sulfonylureas in Patients Who Received Metformin as First-Line Drug Treatment.

*<p>CI denotes confidence interval.</p>†<p>The current cumulative exposure period is the number of months of continuous exposure prior to the event (for cases) or matched index date (controls). Cumulative current exposure includes continuous drug use up until the index date. Exposure that was accumulated prior to any lapse in therapy of greater than 90 days was defined as past exposure.</p>‡<p>Odds ratios have been adjusted for matching variables (age in 5-year groupings, sex, family income band in $5,000 dollar increments, number of family members, and existence of supplemental coverage).</p>§<p>Odds ratios have been adjusted for (in addition to the matching variables) the time since initiation of metformin, the following within 5 years of the index date: congestive heart failure (hospitalization for ICD-9 428 or a physician visit for same plus a prescription for furosemide), angiography, coronary artery bypass graft, percutaneous transluminal angioplasty, ischemic stroke (hospitalization for ICD-9 433, 434, or 436), transient ischemic attack (hospitalization for ICD-9 435), angina (ICD-9 412–414), prior AMI, renal disease (ICD-9 584–586, 403–404); and the following within one year of index: Romano comorbidity score, exposure to nitrates, statins, angiotensen II converting enzyme inhibitors or receptor blockers, thiazide diuretics, calcium channel blockers, beta blockers, clopidogrel, digoxin, warfarin, insulin, and past use of metformin, glitazones and sulfonylureas.</p

Characteristics of Type II Diabetes Patients with Myocardial Infarction and Their Matched Controls^*.

*<p>Odds ratios have been adjusted for matching variables (age in 5-year groupings, sex, family income band in $5,000 dollar increments, number of family members, and existence of supplemental coverage). CI denotes confidence interval.</p>†<p>Net family income band in Canadian dollars from the most recent federal income tax return (1 Canadian dollar = 1.2 US dollars).</p>‡<p>Romano commorbidity score calculated using data from 365 days prior to the index date.</p>§<p>History within 5 years prior to the index date.</p>∥<p>Dispensing of a drug within 365 days prior to index date.</p

Within-Drug Comparison of Glitazone Exposure and Sulfonylurea Exposure in Myocardial Infarction Cases and Matched Controls who received Metformin as First-Line Drug Therapy.

*<p>CI denotes confidence interval.</p>†<p>The current cumulative exposure period is the number of months of continuous exposure prior to the event (for cases) or matched index date (controls). Cumulative current exposure includes continuous drug use up until the index date. Exposure that was accumulated prior to any lapse in therapy of greater than 90 days was defined as past exposure.</p>‡<p>Odds ratios have been adjusted for matching variables (age in 5-year groupins, sex, family income band in $5,000 dollar increments, number of family members, and existence of supplemental coverage).</p>§<p>Odds ratios have been adjusted for (in addition to the matching variables) time since initiation of metformin, the following within 5 years of the index date: congestive heart failure, angiography, coronary artery bypass graft, percutaneous transluminal angioplasty, ischemic stroke, transient ischemic attack, angina, prior AMI, renal disease; and the following within one year of index: Romano comorbidity score, exposure to nitrates, statins, angiotensen II converting enzyme inhibitors or receptor blockers, thiazide diuretics, calcium channel blockers, beta blockers, clopidogrel, digoxin, warfarin, insulin, and past use of metformin, glitazones and sulfonylureas.</p